5 Best Genomics Stocks To Buy Now

3. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Number of Hedge Fund Holders: 52  

Serapta Therapeutics, Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. On November 28, Sarepta Therapeutics noted that the FDA accepted its marketing application for gene therapy candidate SRP-9001 it developed with Roche under the agency’s priority review. 

On November 3, Credit Suisse analyst Judah Frommer maintained a Neutral rating on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock and raised the price target to $101 from $93, noting that the company reported third-quarter earnings with the call largely centered on timelines for SRP-9001.

Among the hedge funds being tracked by Insider Monkey, New York-based investment firm VenBio Select Advisors is a leading shareholder in Serapta Therapeutics, Inc. (NASDAQ:SRPT) with 3.2 million shares worth more than $350.96 million.